Table 1.
Entry |
|
AspH variant |
[s−1] |
[μM] |
/ [mM−1 s−1] |
---|---|---|---|---|---|
1 |
FeII[c] |
wt |
0.24±0.04 |
7.2±2.6 |
33.3±13.2 |
H679A |
0.18±0.01 |
4.4±0.8 |
40.9±7.8 |
||
H725A |
0.09±0.01 |
12.3±3.0 |
7.3±2.0 |
||
2 |
FeII[d] |
wt |
0.27±0.04 |
4.3±1.6 |
62.8±25.2 |
H679A |
0.19±0.01 |
2.7±0.5 |
70.4±13.6 |
||
H725A |
0.10±0.01 |
8.1±1.8 |
12.3±3.0 |
||
3 |
2OG |
wt |
0.31±0.03 |
1.1±0.4 |
282±106 |
H679A |
0.18±0.01 |
109±20 |
1.7±0.3 |
||
H725A |
0.08±0.01 |
211±65 |
0.38±0.13 |
||
4 |
hFX‐EGFD186‐124‐4Ser[e] |
wt[f] |
n.d. |
n.d. |
n.d. |
H679A |
0.18±0.01 |
1.5±0.3 |
120±24.9 |
||
H725A |
0.10±0.02 |
1.7±1.1 |
58.8±39.8 |
[a] Determined using 0.2 μM AspH variant or 0.1 μM wt AspH by SPE‐MS. Detailed analyses are given in Supporting Figures S4–S6. [b] Mean of three independent runs (n=3; mean ± standard deviation, SD). [c] Without L‐ascorbate (LAA). [d] With LAA. [e] and values were determined monitoring the hydroxylation of the hFX‐EGFD186‐124‐4Ser substrate peptide (Supporting Figure S2a). [f] Apparent substrate inhibition combined with low detectability of the peptide at low concentrations prevented determination.